Cutaneous neoplasms in organ transplant recipients (OTR) have traditionally been managed by early detection and treatment. Prevention is also a key factor in managing these patients, and to date this has largely been achieved through education, sun avoidance measures, and early detection with regular clinical reviews. Lately, systemic chemoprevention has emerged as an important modality for treatment whereby clinicians can hope to reduce and/or delay the development of cutaneous neoplasms in these patients.
KeywordsSkin Cancer Basal Cell Carcinoma Renal Transplant Recipient Actinic Keratosis Organ Transplant Recipient
Unable to display preview. Download preview PDF.
- 2.Nguyen EQH, Wolverton SE. Systemic retinoids. In: Wolverton SE (ed) Comprehensive Dermatologic Drug Therapy. Philadelphia: Saunders, 2001:269–310.Google Scholar
- 6.Bouwes Bavinck JN, Tieben LM, van der Woude FJ et al. Prevention of skin cancer and reduction of keratotic lesions during acitretin therapy in renal transplant recipients: a double-blind placebo controlled study. J Clin Oncol 1995; 1933–8.Google Scholar